Development of immunologice-based treatments to recruit the immune system in the fight against cancer. (Q80007): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Created claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Cancer development is shaped by the immune system and the most serious cancers are able to avoid a defensive response of the organism through the use of differ...) |
||
| Property / summary | |||
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Cancer development is shaped by the immune system and the most serious cancers are able to avoid a defensive response of the organism through the use of different mechanisms, including local response to T-cell local responses or the induction of immunology.One of the signs of cancer is the imbalance between the two populations of T & ndash;field and control cells (Treg).The change in the equilibrium between cytotoxicity and depression by fine-tuning the response of T-cell lymphocytes therefore has enormous potential as an anti-cancer strategy.Therefore, one of the fundamental objectives of this project is to control the ratios.Treg to cytotoxicity T (CTL) by modulating control of the cells.Natural cytotoxicity and reactivity towards a wide range of molecular purposes makes the NK cells particularly attractive for therapeutic intervention.Research indicates that these cells are often hyporeactive or dysfunctional in patients with malignant neoplasms making it possible to escape the cancer before the immune system and consequently to the progression of the disease.The second aspect of the project thus involves treating cancer by actively involving NK’s cells at the tumour site.As part of the project, we plan to develop a therapy that strengthens the work of the patient immune system and steering it towards cancer in a way that minimises attack on surrounding healthy tissues. (English) | |||
| Property / summary: Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Cancer development is shaped by the immune system and the most serious cancers are able to avoid a defensive response of the organism through the use of different mechanisms, including local response to T-cell local responses or the induction of immunology.One of the signs of cancer is the imbalance between the two populations of T & ndash;field and control cells (Treg).The change in the equilibrium between cytotoxicity and depression by fine-tuning the response of T-cell lymphocytes therefore has enormous potential as an anti-cancer strategy.Therefore, one of the fundamental objectives of this project is to control the ratios.Treg to cytotoxicity T (CTL) by modulating control of the cells.Natural cytotoxicity and reactivity towards a wide range of molecular purposes makes the NK cells particularly attractive for therapeutic intervention.Research indicates that these cells are often hyporeactive or dysfunctional in patients with malignant neoplasms making it possible to escape the cancer before the immune system and consequently to the progression of the disease.The second aspect of the project thus involves treating cancer by actively involving NK’s cells at the tumour site.As part of the project, we plan to develop a therapy that strengthens the work of the patient immune system and steering it towards cancer in a way that minimises attack on surrounding healthy tissues. (English) / rank | |||
Normal rank | |||
Revision as of 09:01, 4 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of immunologice-based treatments to recruit the immune system in the fight against cancer. |
Project in Poland financed by DG Regio |
Statements
30,130,439.0 zloty
0 references
39,905,405.0 zloty
0 references
75.5 percent
0 references
1 February 2019
0 references
31 December 2023
0 references
PURE BIOLOGICS SPÓŁKA AKCYJNA
0 references
51°7'34.7"N, 16°58'41.5"E
0 references
Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). Rozwój nowotworu kształtowany jest przez układ immunologiczny, a najgroźniejsze nowotwory potrafią unikać obronnej odpowiedzi organizmu poprzez stosowanie różnych mechanizmów, w tym supresji lokalnej odpowiedzi limfocytów T czy indukcji tolerancji immunologicznej. Jedną z oznak nowotworu jest zaburzenie równowagi pomiędzy dwiema populacjami limfocytów T – komórkami efektorowymi (Teff) i regulatorowymi (Treg). Zmiana stanu równowagi pomiędzy cytotoksycznością i supresją poprzez dostrojenie odpowiedzi limfocytów T ma zatem ogromny potencjał jako strategia terapii antynowotworowych. Jednym z podstawowych założeń niniejszego projektu jest więc zatem kontrola stosunku kom. Treg do cytotoksycznych limfocytów T (CTL) poprzez modulację aktywności komórek regulatorowych. Naturalna cytotoksyczność i reaktywność wobec szerokiej gamy celów molekularnych sprawia, że również komórki NK są szczególnie atrakcyjnym celem interwencji terapeutycznej. Badania wskazują, że komórki te są często hipoaktywne lub dysfunkcyjne u pacjentów z nowotworami złośliwymi, co umożliwia ucieczkę kom. nowotworowych przed układem odpornościowym i w konsekwencji progresję choroby. Drugi aspekt projektu zakłada zatem terapię antynowotworową właśnie poprzez aktywne angażowanie komórek NK w miejscu guza. W ramach projektu planujemy opracowanie terapii wzmacniającej pracę układu odpornościowego pacjentów oraz nakierowującej go na zwalczanie kom. nowotworowych w sposób minimalizujący atakowanie otaczających zdrowych tkanek. (Polish)
0 references
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Cancer development is shaped by the immune system and the most serious cancers are able to avoid a defensive response of the organism through the use of different mechanisms, including local response to T-cell local responses or the induction of immunology.One of the signs of cancer is the imbalance between the two populations of T & ndash;field and control cells (Treg).The change in the equilibrium between cytotoxicity and depression by fine-tuning the response of T-cell lymphocytes therefore has enormous potential as an anti-cancer strategy.Therefore, one of the fundamental objectives of this project is to control the ratios.Treg to cytotoxicity T (CTL) by modulating control of the cells.Natural cytotoxicity and reactivity towards a wide range of molecular purposes makes the NK cells particularly attractive for therapeutic intervention.Research indicates that these cells are often hyporeactive or dysfunctional in patients with malignant neoplasms making it possible to escape the cancer before the immune system and consequently to the progression of the disease.The second aspect of the project thus involves treating cancer by actively involving NK’s cells at the tumour site.As part of the project, we plan to develop a therapy that strengthens the work of the patient immune system and steering it towards cancer in a way that minimises attack on surrounding healthy tissues. (English)
0 references
Identifiers
POIR.01.02.00-00-0086/18
0 references